Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Dow
Colorcon
Medtronic
Mallinckrodt
McKinsey
Harvard Business School

Last Updated: November 22, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,601,746

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,601,746 protect, and when does it expire?

Patent 7,601,746 protects MULPLETA and is included in one NDA.

This patent has fifteen patent family members in nine countries.

Summary for Patent: 7,601,746
Title:Compounds exhibiting thrombopoietin receptor agonism
Abstract: A compound represented by the general formula (I): ##STR00001## wherein R.sup.1 is a hydrogen atom, a halogen atom, or the like; R.sup.2, R.sup.3, and R.sup.4 are each independently a hydrogen atom, a halogen atom, C1-C15 alkyl optionally substituted with one or more C1-C12 alkyloxy or the like, or the like; R.sup.5 is a hydrogen atom or the like; R.sup.6 and R.sup.7 are a hydrogen atom or the like; R.sup.8 is C1-C3 alkyl or the like; R.sup.9 is a hydrogen atom or the like), a prodrug, a pharmaceutically acceptable salt, or solvate thereof.
Inventor(s): Takayama; Masami (Osaka, JP), Yoshida; Yutaka (Osaka, JP)
Assignee: Shionogi & Co., Ltd. (Osaka, JP)
Application Number:10/567,993
Patent Claim Types:
see list of patent claims
Use; Composition; Compound;

Drugs Protected by US Patent 7,601,746

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Shionogi Inc MULPLETA lusutrombopag TABLET;ORAL 210923-001 Jul 31, 2018 RX Yes Yes   Start Trial   Start Trial Y Y TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC LIVER DISEASE WHO ARE SCHEDULED TO UNDERGO A PROCEDURE   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,601,746

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2003-292080Aug 12, 2003
PCT Information
PCT FiledAugust 10, 2004PCT Application Number:PCT/JP2004/011453
PCT Publication Date:February 17, 2005PCT Publication Number: WO2005/014561

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
AstraZeneca
Colorcon
Moodys
Dow
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.